Búsqueda de Publicación - Prisma - Unidad de Bibliometría

Publicaciones en la fuente JOURNAL OF CLINICAL ONCOLOGY

Tipo Año Título Fuente
Artículo2024Outcomes with Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238JOURNAL OF CLINICAL ONCOLOGY
Artículo2024Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR -Mutant Non-Small-Cell Lung CancerJOURNAL OF CLINICAL ONCOLOGY
Artículo2024Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.JOURNAL OF CLINICAL ONCOLOGY
Artículo2023Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915)JOURNAL OF CLINICAL ONCOLOGY
Artículo2023Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in checkmate 227JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2023Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 studyJOURNAL OF CLINICAL ONCOLOGY
Artículo2023Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination.JOURNAL OF CLINICAL ONCOLOGY
Artículo2022Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)JOURNAL OF CLINICAL ONCOLOGY
Artículo2021Elective cancer surgery in COVID-19–Free surgical pathways during the SARS-cov-2 pandemic: an international, multicenter, comparative cohort studyJOURNAL OF CLINICAL ONCOLOGY
Artículo2021Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)JOURNAL OF CLINICAL ONCOLOGY
Artículo2021Veliparib in combination with platinum-based chemotherapy for first-line treatment of advanced squamous cell lung cancer: a randomized, multicenter phase III studyJOURNAL OF CLINICAL ONCOLOGY
Artículo2020First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid LeukemiaJOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2020IMMUNOSARC: a collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib and nivolumab in advanced soft tissue and bone sarcoma: Results from the phase II part, bone sarcoma cohort.JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2020Optimizing management of the oncological patient with pulmonary embolism: validation of the epiphany index-PERSEO study.JOURNAL OF CLINICAL ONCOLOGY
Artículo2020Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2019Evolution of the myeloid-derived suppressor cells in advanced breast cancer and comparative analysis with a healthy population cohortJOURNAL OF CLINICAL ONCOLOGY
Artículo2019Influence of HIV infection on the natural history of hepatocellular carcinoma: results from a global multicohort studyJOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2019Multi-institutional european single-arm phase II trial of pazopanib in advanced typical solitary fibrous tumors (SFT): A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups study.JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso201890 yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: Updated results after a median follow-up of 8.5 years from the GOTEL trial.JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2018Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAF(V600) mutation-positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM studyJOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2018IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) Sarcoma Groups phase I/II trial of sunitinib plus nivolumab in selected bone and soft tissue sarcoma subtypes-Results of the phase I part.JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2018Ipilimumab and radiation in patients with unresectable melanoma brain metastases: A multicenter, open label, phase-2, Spanish Melanoma Group (GEM) study (NCT-2013-001132-22)JOURNAL OF CLINICAL ONCOLOGY
Artículo2018Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2017A phase 2 study of investigational TORC1/2 inhibitor TAK-228 with fulvestrant in women with ER+/HER2-advanced or metastatic breast cancer (mBC) that has progressed during or after aromatase inhibitor (AI) therapyJOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2017International single-arm phase II trial of pazopanib in advanced extraskeletal myxoid chondrosarcoma: A Collaborative Spanish (GEIS), Italian (ISG) and French (FSG) Sarcoma Groups study.JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2017Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphomaJOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2017Multi-institutional European single-arm phase II trial of pazopanib in advanced malignant/dedifferentiated solitary fibrous tumors (SFT): A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups studyJOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2017Phase II multicenter, single arm, open label study of nivolumab (NIVO) in combination with ipilimumab (IPI) as first line in adult patients (pts) with metastatic uveal melanoma (MUM): GEM1402 NCT02626962.JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2016GEIS-21: A multicentric phase II study of intensive chemotherapy including gemcitabine/docetaxel for the treatment of Ewing sarcoma of children and adults: A report from the Spanish Group of Sarcoma Investigation (GEIS).JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2015Chemotherapy effectiveness in the treatment of non-medullary well-differentiated thyroid cancer: A systematic reviewJOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2015EGFR testing by a new diagnostic method to detect point mutations, deletions and insertions associated to non small cell lung cancer: CLART CMA EGFR.JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2015Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C)JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2015Sym004 to circumvent resistance to cetuximab driven by emergence of EGFR extracellular mutations in colorectal cancer.JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2015Targeting the PI3K/AKT/mTOR pathway with MLN0128 (mTORC1/2 inh) and MLN1117 (PI3K alpha inh) in bladder cancer: Rational for its testing in clinical trialsJOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2015Targeting the PI3K/AKT/mTOR pathway with MLN0128 (mTORC1/2 inh) and MLN1117 (PI3K alpha inh) in bladder cancer: Rational for its testing in clinical trials.JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2015Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanomaJOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2014A phase 1 mechanism of action study of intratumoral or intravenous administration of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus in colon cancer patients undergoing resection of primary tumor.JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2014Concordance of ColoPrint and MSI-print classification in paired endoscopic-surgical specimens of stage I-III colorectal cancer (CRC).JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2014Evaluation of changes on tumor-infiltrating lymphocytes and regulatory T-cells in tissue and peripheral blood after neoadjuvant chemotherapy in breast cancer patients and relation with pathologic complete responseJOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2014Outpatient management of cancer-related pulmonary embolism: Analysis of 562 consecutive patients from the EPIPHANY study.JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2013Assessment of treatment response with fulvestrant (F) 500 mg in standard clinical practice through a retrospective study: NCT01509625JOURNAL OF CLINICAL ONCOLOGY
Ponencia2013Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 studyJOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2013Pathologic complete response and changes related to T-infiltrating lymphocytes and regulatory T cells in tissue and peripheral blood after neoadjuvant chemotherapy in breast carcinomaJOURNAL OF CLINICAL ONCOLOGY
Ponencia2013Relevance of MIA and S-100 to monitor BRAF inhibitor (iBRAF) therapy in metastatic melanoma patientsJOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2013Study of lapatinib (T) in combination with trastuzumab (T) in women heavily pretreated with HER2-positive metastatic breast cancer (MBC)JOURNAL OF CLINICAL ONCOLOGY
Ponencia2012Use of Cobas 4800 BRAF mutation test for the analysis of BRAF V600 mutations in cytological samples (CS) from metastatic melanoma (MM)JOURNAL OF CLINICAL ONCOLOGY
Letter2011Allogeneic Hematopoietic Stem-Cell Transplantation for Myeloma: It's Time for the Appropriate Studies ReplyJOURNAL OF CLINICAL ONCOLOGY
Artículo2011Excellent Outcome With Reduced Treatment in Infants With Nonmetastatic and Unresectable Neuroblastoma Without MYCN Amplification: Results of the Prospective INES 99.1JOURNAL OF CLINICAL ONCOLOGY
Ponencia2011Feasability and reliabity of the assessment of BRAF and c-KIT mutations in cytologic samples from metastatic melanoma.JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2011Treatment of Ewing sarcoma family of tumors with a modified P6 protocol in children and adolescents: Analysis of growth signaling pathways expression and clinical outcome.JOURNAL OF CLINICAL ONCOLOGY
Ponencia2010Chronology of the arterial hypertension associated with inhibiting treatments of vascular endothelium growth factor receptor in patients with cancerJOURNAL OF CLINICAL ONCOLOGY
Revisión2010International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple MyelomaJOURNAL OF CLINICAL ONCOLOGY
Artículo2009Autologous Stem-Cell Transplantation in Patients With HIV-Related LymphomaJOURNAL OF CLINICAL ONCOLOGY
Corrección2009Autologous Stem-Cell Transplantation in Patients With HIV-Related Lymphoma (vol 27, pg 2192, 2009)JOURNAL OF CLINICAL ONCOLOGY
Ponencia2009PRIMARY BREAST SARCOMA: CLINICAL AND RETROSPECTIVE ANALYSIS OF CASES FROM JEREZ GENERAL HOSPITAL, SPAINJOURNAL OF CLINICAL ONCOLOGY
Ponencia2008Multicenter study of weekly trastuzumab, paclitaxel, and carboplatin followed by a week of rest every 28 days in patients with HER2+ metastatic breast cancer JOURNAL OF CLINICAL ONCOLOGY
Artículo2008Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: Chronic graft-versus-host disease is the strongest factor improving survivalJOURNAL OF CLINICAL ONCOLOGY
Ponencia2007MULTICENTER STUDY OF WEEKLY TRASTUZUMAB, PACLITAXEL AND CARBOPLATIN FOLLOWED BY A WEEK OF REST EVERY 28 DAYS IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER (MBC).JOURNAL OF CLINICAL ONCOLOGY
Artículo2007Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancerJOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2007Subgroup analysis of GEICAM 9906 trial comparing six cycles of FE90C (FEC) to four cycles of FE90C followed by 8 weekly paclitaxel administrations (FECP): Relevance of HER2 and hormonal status (HR)JOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2006Neuregulin (NRG) expression modulates clinical response to trastuzumab in patients with metastatic breast cancer (MBC).JOURNAL OF CLINICAL ONCOLOGY
Ponencia2005DOCETAXEL FOLLOWED BY CAPECITABINE AS FIRST-LINE CHEMOTHERAPY IN METASTATIC BREAST CANCER PATIENTS: PRELIMINARY RESULTSJOURNAL OF CLINICAL ONCOLOGY
Resumen congreso2004A multicenter sequential phase IV study of oxaliplatin (Oxa) and capecitabine (Cap) followed by irinotecan (Iri) and capecitabine in first line advanced colorectal cancer (ACC). Preliminary resultsJOURNAL OF CLINICAL ONCOLOGY
Artículo2004Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomasJOURNAL OF CLINICAL ONCOLOGY
Artículo2000Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor familyJOURNAL OF CLINICAL ONCOLOGY
Artículo1999EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcomaJOURNAL OF CLINICAL ONCOLOGY
Artículo1998Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): Desmoplastic small round-cell tumor and its variantsJOURNAL OF CLINICAL ONCOLOGY
Artículo1998EWS-FL11 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcomaJOURNAL OF CLINICAL ONCOLOGY